Medpace Holdings, Inc. $MEDP Shares Acquired by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services increased its stake in Medpace by 44.4% in Q4 to 21,942 shares, worth about $13.44 million, as part of institutional ownership totaling 77.98%.
• Insider sale: President Jesse J. Geiger sold 31,707 shares at an average price of $455.30 for roughly $14.44 million, cutting his position by 67.88%; insiders now own 20.30% of the company.
• Strong quarterly results and guidance: Medpace reported EPS of $4.67 (vs. $4.18 expected) and revenue of $708.45M (vs. $689.53M expected), set FY2026 guidance of $16.68–$17.50 EPS, and trades with a market cap of $13.24B and a P/E of 30.5.

Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 44.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,942 shares of the company's stock after buying an additional 6,749 shares during the period. Wealth Enhancement Advisory Services LLC owned 0.08% of Medpace worth $13,437,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Clarkston Capital Partners LLC acquired a new stake in shares of Medpace in the 2nd quarter worth about $40,569,000. Cibc World Market Inc. bought a new position in Medpace in the 3rd quarter worth about $5,033,000. Brighton Jones LLC increased its stake in shares of Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company's stock valued at $2,087,000 after purchasing an additional 2,501 shares during the period. Capital Fund Management S.A. increased its stake in shares of Medpace by 129.5% in the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company's stock valued at $16,665,000 after purchasing an additional 18,287 shares during the period. Finally, Baillie Gifford & Co. boosted its position in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company's stock worth $300,679,000 after buying an additional 62,503 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on MEDP shares. Zacks Research cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 12th. Wall Street Zen upgraded Medpace from a "hold" rating to a "buy" rating in a research report on Saturday, January 17th. Leerink Partners decreased their price target on Medpace from $575.00 to $485.00 and set a "market perform" rating for the company in a research note on Wednesday, February 11th. BMO Capital Markets reissued a "market perform" rating on shares of Medpace in a report on Wednesday, February 11th. Finally, Barclays raised shares of Medpace from an "underweight" rating to an "equal weight" rating and set a $500.00 price objective for the company in a report on Friday, March 6th. Five research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $486.67.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company's stock, valued at $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 20.30% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $466.60 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The firm has a market cap of $13.24 billion, a P/E ratio of 30.50, a PEG ratio of 2.24 and a beta of 1.44. The stock has a fifty day moving average price of $497.26 and a two-hundred day moving average price of $537.33.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company's quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.